Continuous Subcutaneous Insulin Infusion

DEVICE4 trials

Sponsors

Newcastle University, King's College London, University of Virginia, First Affiliated Hospital of Guangxi Medical University

Conditions

Diabetes Mellitus, Type 2Type 1 Diabetes MellitusType2diabetes

Phase 4

Prevention of Severe Hypoglycemia in Type 1 Diabetes

CompletedNCT00360984

Newcastle UniversityType 1 Diabetes Mellitus

Start: 2003-05-31End: 2004-09-30Target: 21Updated: 2006-08-07

Combination of Henagliflozin and Continuous Subcutaneous Insulin Infusion in T2DM

CompletedNCT05677334

First Affiliated Hospital of Guangxi Medical UniversityType2diabetes

Start: 2023-03-01End: 2024-10-30Updated: 2025-03-12

Unknown Phase

Individual Patient Data Meta-analysis of CSII vs. MDI in Type 2 Diabetes

CompletedNCT02910141

King's College LondonDiabetes Mellitus, Type 2

Start: 2014-01-31End: 2016-12-31Updated: 2017-03-03

Artificial Pancreas and Remote Monitoring During a T1DM Youth Ski Camp

CompletedNCT03369067

University of VirginiaType 1 Diabetes Mellitus

Start: 2017-12-18End: 2018-04-15Updated: 2024-10-01

Related Papers

A Multicentre, Randomised, Controlled, Open-Label Study of Continuous Subcutaneous Insulin Infusion Plus Henagliflozin for Treating Type 2 Diabetes Mellitus Patients With Severe Hyperglycaemia.

2026-03-19

Efficacy and safety of henagliflozin combined with continuous subcutaneous insulin infusion in the treatment of Chinese inpatients with type 2 diabetes mellitus based on a continuous glucose monitoring system: protocol of a multicentre, open-label, inpatient, randomised, controlled trial

BMJ Open2024-10-011 citations

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01